Literature DB >> 11696470

Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia.

N H Buus1, M Bøttcher, F Hermansen, M Sander, T T Nielsen, M J Mulvany.   

Abstract

BACKGROUND: Myocardial perfusion during adenosine-induced hyperemia is used both in clinical diagnosis of coronary heart disease and for scientific investigations of the myocardial microcirculation. The objective of this study was to clarify whether adenosine-induced hyperemia is dependent on endothelial NO production or is influenced by adrenergic mechanisms. METHODS AND
RESULTS: In 12 healthy men, myocardial perfusion was measured with PET in 2 protocols performed in random order, each including 3 perfusion measurements. First, perfusion was measured at rest. Second, either saline or the NO synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME, 4 mg/kg) was infused, and perfusion during adenosine-induced hyperemia was determined. Last, in both protocols, the alpha-receptor blocker phentolamine was infused, and perfusion during adenosine-induced hyperemia was determined again. Resting perfusion was similar in the 2 protocols (0.69+/-0.14 and 0.66+/-0.18 mL. min(-1). g(-1)). L-NAME increased mean arterial blood pressure by 12+/-7 mm Hg (P<0.01) and reduced heart rate by 16+/-7 bpm (P<0.01). Adenosine-induced hyperemia (1.90+/-0.33 mL. min(-1). g(-1)) was attenuated by L-NAME (1.50+/-0.55 mL. min(-1). g(-1), P<0.01). The addition of phentolamine had no effect on the adenosine-induced hyperemia (2.10+/-0.34 mL. min(-1). g(-1), P=NS). In the presence of L-NAME, however, when the adenosine response was attenuated, phentolamine was able to increase hyperemic perfusion (2.05+/-0.44 mL. min(-1). g(-1), P<0.05).
CONCLUSIONS: Inhibition of endogenous NO synthesis attenuates myocardial perfusion during adenosine-induced hyperemia, indicating that coronary vasodilation by adenosine is partly endothelium dependent. alpha-Adrenergic blockade has no effect on adenosine-induced hyperemia unless NO synthesis is inhibited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696470     DOI: 10.1161/hc4401.098293

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  48 in total

1.  Assessment of coronary flow reserve and microcirculation: a clinical perspective.

Authors:  Roxana Campisi; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

2.  Augmentation of limb perfusion and reversal of tissue ischemia produced by ultrasound-mediated microbubble cavitation.

Authors:  J Todd Belcik; Brian H Mott; Aris Xie; Yan Zhao; Sajeevani Kim; Nathan J Lindner; Azzdine Ammi; Joel M Linden; Jonathan R Lindner
Journal:  Circ Cardiovasc Imaging       Date:  2015-04       Impact factor: 7.792

3.  Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography.

Authors:  Erick Alexanderson; Patricio Cruz; Angélica Vargas; Aloha Meave; Alejandro Ricalde; Jose A Talayero; José Luis Romero-Ibarra; Tovë M Goldson; Olga L Vera-Lastra; Gabriela Medina; Luis Jara; Mary-Carmen Amigo
Journal:  J Nucl Cardiol       Date:  2007-07-02       Impact factor: 5.952

4.  PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction.

Authors:  Thomas H Schindler; Alvaro D Facta; John O Prior; Roxana Campisi; Masayuki Inubushi; Michael C Kreissl; Xiao-Li Zhang; James Sayre; Magnus Dahlbom; Heinrich R Schelbert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

Review 5.  Role of PET in the evaluation and understanding of coronary physiology.

Authors:  Thomas H Schindler; Xiao-Li Zhang; Gabriella Vincenti; Leila Mhiri; René Lerch; Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

6.  Assessment of coronary flow reserve by sestamibi imaging in patients with typical chest pain and normal coronary arteries.

Authors:  Giovanni Storto; Anna Rita Sorrentino; Teresa Pellegrino; Raffaele Liuzzi; Mario Petretta; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 9.236

7.  "Mismatch" in regional myocardial perfusion defects during exercise and pharmacologic vasodilation: a noninvasive marker of epicardial vasomotor dysfunction?

Authors:  Thomas H Schindler; Heinrich H Schelbert
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

8.  Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction.

Authors:  Thomas H Schindler; Xiao-Li Zhang; Gabriella Vincenti; Leila Mhiri; Rene Nkoulou; Hanjoerg Just; Osman Ratib; Francois Mach; Magnus Dahlbom; Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

9.  Diabetic background retinopathy is associated with impaired coronary vasoreactivity in people with Type 1 diabetes.

Authors:  J Sundell; T Janatuinen; T Rönnemaa; O T Raitakari; J Toikka; P Nuutila; J Knuuti
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

10.  Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition.

Authors:  Birger Hesse; Christian Meyer; Flemming S Nielsen; Asako Sato; Jens D Hove; Soeren Holm; Lia E Bang; Klaus F Kofoed; Tage L Svendsen; Hans-Henrik Parving; Lionel H Opie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.